These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 8678496

  • 1. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
    Sonoo H, Senoo T, Nishiki M, Morimoto T, Takashima S.
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
    [Abstract] [Full Text] [Related]

  • 2. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
    Noguchi S, Yamamoto H, Inaii H, Koyama H.
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
    [Abstract] [Full Text] [Related]

  • 3. [Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer].
    Mitsuyama S, Kuroda Y, Ohsato K, Nakamura Y, Murakami F, Nishikata F, Ikeda S, Egami T, Mori A, Ohe H.
    Gan To Kagaku Ryoho; 1996 Aug; 23(9):1153-60. PubMed ID: 8751803
    [Abstract] [Full Text] [Related]

  • 4. [Comparison of CAF plus MPA with CAF plus TAM for advanced or recurrent breast cancer--Kyushu CAFT Study Group of Advanced or Recurrent Breast Cancer].
    Mitsuyama S, Tashiro H, Koga T, Maehara Y, Ogawa M, Kakegawa T, Shimazu H, Sugimachi K, Tomita M, Nakamura Y.
    Gan To Kagaku Ryoho; 1995 Dec; 22(14):2073-80. PubMed ID: 8607618
    [Abstract] [Full Text] [Related]

  • 5. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H, Sakai K, Oka T, Ozawa K, Saito Y, Senoo T, Taguchi T, Terasawa T, Nakao K, Mori T, Koyama H, Oshima A.
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [Abstract] [Full Text] [Related]

  • 6. [Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)].
    Mitsuyama S, Ohno S, Koga T, Takayama T, Yamashita J, Ogawa M, Shirouzu K, Sugimachi K, Nomura Y, Ogawa N.
    Gan To Kagaku Ryoho; 1999 Nov; 26(13):2029-36. PubMed ID: 10584567
    [Abstract] [Full Text] [Related]

  • 7. [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer].
    Aikawa T, Yayoi E, Takatsuka Y, Maeura Y, Miyauchi K.
    Gan To Kagaku Ryoho; 1991 May; 18(6):995-1002. PubMed ID: 1827575
    [Abstract] [Full Text] [Related]

  • 8. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L, Burghouts J, van Turnhout J, Breed W, Hillen H, Holdrinet A, Boetius G, Hoogendoorn G, Doesburg W, Verhulst M.
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [Abstract] [Full Text] [Related]

  • 9. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).
    Beex L, Rose C, Mouridsen H, Jassem J, Nooij M, Estape J, Paridaens R, Piccart M, Gorlia T, Lardenoije S, Baila L.
    Eur J Cancer; 2006 Dec; 42(18):3178-85. PubMed ID: 17045796
    [Abstract] [Full Text] [Related]

  • 10. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
    Ingle JN, Green SJ, Ahmann DL, Edmonson JH, Nichols WC, Frytak S, Rubin J.
    Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
    [Abstract] [Full Text] [Related]

  • 11. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PG, Stewart J.
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [Abstract] [Full Text] [Related]

  • 12. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
    Beltrán M, Alonso MC, Ojeda MB, Izquierdo A, Ferrer J, Picó C, Anglada L, Catalán G, Batiste-Alentorn E, Tusquets I.
    Ann Oncol; 1991 Jul; 2(7):495-9. PubMed ID: 1832944
    [Abstract] [Full Text] [Related]

  • 13. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
    Giralt E, Jouve M, Palangie T, Bretaudeau B, Asselain B, Magdelenat H, Merle S, Zajdela A, Pouillart P.
    Bull Cancer; 1984 Jul; 71(1):22-9. PubMed ID: 6324934
    [Abstract] [Full Text] [Related]

  • 14. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T, Izuo M, Nomura Y, Kubo K, Abe O, Enomoto K, Takatani O.
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
    Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, Loprinzi CL, Perez EA, Jordan VC, Dowsett M.
    Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
    [Abstract] [Full Text] [Related]

  • 16. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L, Durand M, Bonichon F, Chauvergne J.
    Bull Cancer; 1986 Jul; 73(2):148-54. PubMed ID: 2942203
    [Abstract] [Full Text] [Related]

  • 17. [Chemo-endocrine therapy with high dose medroxyprogesterone acetate for recurrent or advanced breast cancer].
    Maeda T, Kubo Y, Sasajima T, Ikeda K, Hirata S, Yamazaki K, Nakajima S.
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2165-9. PubMed ID: 8239681
    [Abstract] [Full Text] [Related]

  • 18. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F, Martoni A, Piana E, Tomasi L, Grieco A, Farris A, Saccani F, Baroni M.
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [Abstract] [Full Text] [Related]

  • 19. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, Akazawa K, Abe O.
    J Clin Oncol; 2005 Apr 01; 23(10):2172-84. PubMed ID: 15800310
    [Abstract] [Full Text] [Related]

  • 20. [Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].
    Gershanovich ML, Garin AM, Baltinia D, Kurvet A, Kangas L, Ellmen Iu.
    Vopr Onkol; 1997 Apr 01; 43(6):587-95. PubMed ID: 9479357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.